About this Research Topic
The interplay between APOBEC (Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like) and ADAR (Adenosine Deaminases Acting on RNA) enzymes in oncogenesis represents a frontier in cancer research. APOBEC and ADAR are involved in RNA editing and DNA mutation processes, contributing to genetic variations and instability in cells. Their dysregulation has been linked to the development and progression of various cancers. Understanding the molecular mechanisms of these enzymes is crucial, as they offer potential therapeutic targets. With the evolving landscape of cancer genomics and targeted therapy, research in this area is increasingly significant. The exploration of APOBEC and ADAR’s roles not only provides insight into cancer biology but also opens new avenues for innovative treatments.
This Research Topic aims to delve into the complex roles of APOBEC and ADAR in oncogenesis, focusing on unraveling their molecular mechanisms and evaluating their potential as therapeutic targets. Despite the advancements in understanding these enzymes, several questions remain unanswered. How do APOBEC and ADAR contribute to tumorigenesis and tumor progression? What are the specific pathways and interactions involved? Most importantly, how can this knowledge be translated into effective cancer therapies? This topic seeks to address these critical questions, aiming to bridge the gap between molecular biology and clinical application. By examining the latest research and fostering interdisciplinary discussions, the goal is to advance our understanding of cancer biology and enhance the development of targeted therapies. We plan to seek more deeper knowledge of molecular characterization of APOBEC and ADAR enzymes in cancer; the role of these enzymes in genetic variations and instability within tumors; pathways and interactions involving APOBEC and ADAR in cancer development; potential therapeutic strategies targeting these enzymes; translational research linking laboratory findings to clinical applications in oncology.
We welcome original research articles, systematic review, meta-analysis, clinical case studies, and review articles within the scope of the research topic. Bioinformatics studies are welcome; however, these should not be based solely on analysis of publicly available datasets such as TCGA. It is essential to have an independent validation cohort for statistically significant confirmation of the findings communicated. The submissions can include but not limited to the following subtopics:
•Comprehensive reviews on the biology of APOBEC and ADAR enzymes in oncogenesis.
•Original research articles detailing novel insights into the molecular mechanisms of APOBEC and ADAR in cancer.
•Studies exploring the therapeutic potential of targeting APOBEC and ADAR in cancer treatment.
•Reports on the clinical implications of APOBEC and ADAR dysregulation in cancer patients.
•Interdisciplinary research bridging molecular biology, genomics, and clinical oncology.
•Manuscripts should provide clear methodology, robust data analysis, and discuss the implications of findings in the broader context of cancer research and treatment.
This Research Topic aims to delve into the complex roles of APOBEC and ADAR in oncogenesis, focusing on unraveling their molecular mechanisms and evaluating their potential as therapeutic targets. Despite the advancements in understanding these enzymes, several questions remain unanswered. How do APOBEC and ADAR contribute to tumorigenesis and tumor progression? What are the specific pathways and interactions involved? Most importantly, how can this knowledge be translated into effective cancer therapies? This topic seeks to address these critical questions, aiming to bridge the gap between molecular biology and clinical application. By examining the latest research and fostering interdisciplinary discussions, the goal is to advance our understanding of cancer biology and enhance the development of targeted therapies. We plan to seek more deeper knowledge of molecular characterization of APOBEC and ADAR enzymes in cancer; the role of these enzymes in genetic variations and instability within tumors; pathways and interactions involving APOBEC and ADAR in cancer development; potential therapeutic strategies targeting these enzymes; translational research linking laboratory findings to clinical applications in oncology.
We welcome original research articles, systematic review, meta-analysis, clinical case studies, and review articles within the scope of the research topic. Bioinformatics studies are welcome; however, these should not be based solely on analysis of publicly available datasets such as TCGA. It is essential to have an independent validation cohort for statistically significant confirmation of the findings communicated. The submissions can include but not limited to the following subtopics:
•Comprehensive reviews on the biology of APOBEC and ADAR enzymes in oncogenesis.
•Original research articles detailing novel insights into the molecular mechanisms of APOBEC and ADAR in cancer.
•Studies exploring the therapeutic potential of targeting APOBEC and ADAR in cancer treatment.
•Reports on the clinical implications of APOBEC and ADAR dysregulation in cancer patients.
•Interdisciplinary research bridging molecular biology, genomics, and clinical oncology.
•Manuscripts should provide clear methodology, robust data analysis, and discuss the implications of findings in the broader context of cancer research and treatment.
Keywords: APOBEC, ADAR, Oncogenic Mechanisms, Cancer Therapeutics, Molecular Targeting in Cancer
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
